Menu
Search
|

Menu

Close
X

Recro Pharma Inc REPH.OQ (NASDAQ Stock Exchange Capital Market)

8.61 USD
-- (--)
As of Feb 22
chart
Previous Close 8.61
Open --
Volume --
3m Avg Volume 25,084
Today’s High --
Today’s Low --
52 Week High 10.55
52 Week Low 5.85
Shares Outstanding (mil) 19.13
Market Capitalization (mil) 164.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
53
FY16
69
FY15
52
EPS (USD)
FY17
-1.364
FY16
-2.814
FY15
0.103
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
2.35
8.23
Price to Book (MRQ)
vs sector
3.31
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
50.13
15.44
LT Debt to Equity (MRQ)
vs sector
50.13
12.05
Return on Investment (TTM)
vs sector
-27.85
13.63
Return on Equity (TTM)
vs sector
-80.63
15.25

EXECUTIVE LEADERSHIP

Wayne Weisman
Independent Chairman of the Board, Since 2008
Salary: --
Bonus: --
Geraldine Henwood
President, Chief Executive Officer, Director, Since 2008
Salary: $285,375.00
Bonus: $205,000.00
Ryan Lake
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Michael Celano
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Jyrki Mattila
Executive Vice President - Business Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

490 Lapp Rd
MALVERN   PA   19355-1212

Phone: +1484.3952400

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

SPONSORED STORIES